Modulation of polypeptide expression by novel gene switch expression systems
By using a ligand-inducible gene switch system, the safety and efficacy issues in CAR and TCR adoptive T-cell therapies have been resolved, enabling precise control of heterologous gene expression and improving treatment efficacy and safety.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- PRECIGEN INC
- Filing Date
- 2018-01-10
- Publication Date
- 2026-06-19
AI Technical Summary
Existing CAR and TCR adoptive T-cell immunotherapies have safety issues when killing tumor cells, such as tumor lysis and cytokine release syndrome. Furthermore, expressing CAR or TCR alone may not be sufficient to achieve effective treatment, and additional cytokine expression may be required, which could lead to additional safety issues.
A ligand-inducible gene switch system is used to achieve precise control of heterologous gene expression by encoding gene switch peptides and polynucleotides. The system includes a first gene switch peptide and a second gene switch peptide linked by a linker, which bind to the DNA-binding domain and the transactivation domain, and uses the nuclear receptor ligand binding domain to regulate gene expression.
It achieves precise control over the expression of heterologous genes, reduces or eliminates unwanted side effects, and improves the safety and effectiveness of treatment by providing the restoration of heterologous gene expression.
Smart Images
Figure CN118406655B_ABST